Weimai Qingtong Medical Technology (Wuxi) Co., Ltd. announced that it has received nears CNY 100 million in a round of funding on March 13, 2024. The transaction involved participation from new investor CDH Investment Management Company Limited, Changzhou Lizhong Investment Management Co., Ltd., Yunnan Botanee Bio-Technology Group Co.LTD, Guangdong Evergreen Conglomerate Co., Ltd.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
59.91 CNY | -3.04% | +4.81% | -12.12% |
04-29 | Jefferies Adjusts Yunnan Botanee Bio-Technology’s Price Target to 62 Yuan From 87 Yuan, Keeps at Hold | MT |
04-26 | Yunnan Botanee Bio-Technology Group Co.LTD Proposes Final Dividend for 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.12% | 3.6B | |
+0.62% | 261B | |
+19.64% | 19.93B | |
0.00% | 18.65B | |
+6.07% | 11.53B | |
-10.06% | 9.7B | |
+17.79% | 7.6B | |
+14.08% | 6.32B | |
+2.13% | 4.71B | |
-15.27% | 3.86B |
- Stock Market
- Equities
- 300957 Stock
- News Yunnan Botanee Bio-Technology Group Co.LTD
- Weimai Qingtong Medical Technology Co., Ltd. announced that it has received funding from CDH Investment Management Company Limited, Changzhou Lizhong Investment Management Co., Ltd., Yunnan Botanee Bio-Technology Group Co.LTD, Guangdong Evergreen Conglomerate Co., Ltd.